In conclusion, our results indicate that pemetrexed can induce PD-L1 upregulation in human NSCLC cells by regulating the TS−ROS−NF-κB regulatory axis and prime a favorable tumor microenvironment for ICB therapy (figure 6E). Here, CD274 is linked to neoplasm.